在患有特杜格卢提德肠道衰竭的儿童中,保留结肠片段的延迟呈现
Rachel C Bordelon1, Sarah J Varalla1,2, Varaha S Tammisetti3
1Department of Pediatric Surgery McGovern Medical School at the University of Texas Health Science Center at Houston Houston Texas USA.
JPGN reports
|November 17, 2025
概括
一名患有短肠综合征的儿科患者的特杜格卢类药物治疗发现了一种罕见的并发症. 一个十年前保留的结肠部分在用类似于葡萄糖类2 (GLP-2) 的类似物治疗后变得具有临床意义.
科学领域:
- 胃肠病学 胃肠病学
- 儿科手术 儿科手术
- 药理学 药理学是指药理学的学科.
背景情况:
- 泰杜格卢提德是一种类似葡萄糖类2 (GLP-2) 的类似物,已获得FDA批准用于儿科短肠综合征 (SBS).
- GLP-2类似物增强肠道的适应性和吸收能力,减少对肠道的营养需求.
- 在GLP-2模拟疗法中存在扩散性并发症的理论风险.
研究的目的:
- 报告一个小儿病患的异常病例,该病患接受了teduglutide治疗.
- 为了突出与特异性手术病史患者的特杜格卢类治疗相关的潜在并发症.
主要方法:
- 一个患有短肠综合征的儿科患者的病例报告.
- 审查患者的病史,包括婴儿期之前的外科手术.
- 在服用泰杜格卢胺治疗期间的临床观察.
主要成果:
- 在该患者身上发现了一段10年前不连续的结肠保留段.
- 这种保留的部分在接受了特杜格卢提德治疗后变得具有临床意义.
- 该案例说明了一种罕见的,可能是 teduglutide 治疗的意外后果.
结论:
- 在患有复杂外科病史的患者中,泰杜格卢类药物治疗可能与意想不到的临床事件有关.
- 留住的肠段,即使是长期存在的,也可能对GLP-2模拟治疗产生反应.
- 对于在接受特杜格卢德的儿科患者中可能出现的增殖并发症,需要进一步警.
相关概念视频
Inflammatory Bowel Disease V: Surgical Management
430
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
430
Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy
357
This lesson explores three gastrointestinal imaging techniques: radionuclide testing, colonic transit studies, and virtual colonoscopy.
Radionuclide Testing
Radionuclide testing is a sophisticated medical technique for assessing gastrointestinal motility. It focuses on gastric emptying and colonic transit time. Radioactive markers track the movement of food through the digestive system, providing insights into gastrointestinal disorders.
In gastric emptying studies, a meal's liquid and...
Radionuclide Testing
Radionuclide testing is a sophisticated medical technique for assessing gastrointestinal motility. It focuses on gastric emptying and colonic transit time. Radioactive markers track the movement of food through the digestive system, providing insights into gastrointestinal disorders.
In gastric emptying studies, a meal's liquid and...
357
Gastrointestinal Motility Disorders
1.1K
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
1.1K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
722
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
722
Drugs for Treatment of Diarrhea-Predominant IBS
612
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
612
Drugs for Treatment of Constipation-Predominant IBS
686
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
686


